Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases

Saved in:
Bibliographic Details
Published inJoint, bone, spine : revue du rhumatisme Vol. 88; no. 6; pp. 105226 - 4
Main Authors Trefond, Ludovic, Drumez, Elodie, Andre, Marc, Costedoat-Chalumeau, Nathalie, Seror, Raphaèle, Devaux, Mathilde, Dernis, Emmanuelle, Dieudonné, Yannick, El Mahou, Soumaya, Lanteri, Aurelia, Melki, Isabelle, Queyrel, Viviane, Roumier, Mathilde, Schmidt, Jean, Barnetche, Thomas, Thomas, Thierry, Cacoub, Patrice, Belot, Alexandre, Aumaitre, Olivier, Richez, Christophe, Hachulla, Eric
Format Journal Article
LanguageEnglish
Published Elsevier Masson SAS 01.12.2021
Elsevier Masson
Société française de rhumatologie. Published by Elsevier Masson SAS
Subjects
COVID-19
DMARD
Hydroxychloroquine
Inflammatory rheumatic and musculoskeletal diseases
Letter to the Editor
Life Sciences
Microbiology and Parasitology
SARS COV-2 evolution
SARS CoV-2 tests
COVID-19
Inflammatory rheumatic and musculoskeletal diseases
DMARD
SARS CoV-2 tests
Hydroxychloroquine
SARS COV-2 evolution
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
PMCID: PMC8152361
List of consortium and contributors is available in Online material, supplementary data S3.
ISSN:1297-319X
1778-7254
1778-7254
DOI:10.1016/j.jbspin.2021.105226